Publications by authors named "Dirk B Mendel"

Claim this Profile
C
CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.
Dirk B Mendel, Julie M Cherrington, A Douglas Laird

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of AMG 416 and cinacalcet in rodent models of uremia.
Sarah Walter, Amos Baruch, Shawn T Alexander, Julie Janes, Eiketsu Sho, Dirk B Mendel

BMC Nephrol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational sciences approach to RSV vaccine development.
Vanessa Kurzweil, Roderick Tang, Mark Galinski, Kathy Wang, Fengrong Zuo, Dirk B Mendel

Expert Rev Vaccines· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.
Sarah Walter, Amos Baruch, Jin Dong, James E Tomlinson, Shawn T Alexander, Dirk B Mendel

J Pharmacol Exp Ther· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel robust hepatitis C virus mouse efficacy model.
Qing Zhu, Yoko Oei, Dirk B Mendel, Evelyn N Garrett, Montesa B Patawaran

Antimicrob Agents Chemother· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xiaohua Xin, Tinya J Abrams, Paul W Hollenbach, Katherine G Rendahl, Yan Tang, Dirk B Mendel

Clin Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Shem Patyna, A Douglas Laird, Dirk B Mendel, Anne-Marie O'farrell, Chris Liang

Mol Cancer Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Olga Potapova, A Douglas Laird, Michelle A Nannini, Angela Barone, Guangmin Li, Dirk B Mendel

Mol Cancer Ther· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
Katherine G Moss, Guy C Toner, Julie M Cherrington, Dirk B Mendel, A Douglas Laird

J Pharmacol Exp Ther· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
James G Christensen, Randall Schreck, Jon Burrows, Poonam Kuruganti, Emily Chan, Dirk B Mendel

Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
Cheryl A London, Alison L Hannah, Regina Zadovoskaya, May B Chien, Cynthia Kollias-Baker, Dirk B Mendel

Clin Cancer Res· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
A Douglas Laird, Guangmin Li, Katherine G Moss, Robert A Blake, Martin A Broome, Dirk B Mendel

Mol Cancer Ther· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen

Clin Cancer Res· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Michael Z Wang, Chun Y Tai, Dirk B Mendel

Antimicrob Agents Chemother· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Albert T Liao, May B Chien, Narmada Shenoy, Dirk B Mendel, Gerald McMahon

Blood· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
A Douglas Laird, Jmes G Christensen, Guangmin Li, Jeremy Carver, Kimberly Smith, Dirk B Mendel

FASEB J· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.
Edmund S Ho, Deborah C Lin, Dirk B Mendel, Tomas Cihlar

J Am Soc Nephrol· March 2000

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis